bluebird bio Inc. (NASDAQ:BLUE) finished Wednesday with a subtraction of -$0.31 to close at $20.12, a downside of -1.52 percent. An average of 937,740 shares of common stock have been traded in the last five days. There was a gain of $1.64 in the past week. The last 20 days have seen an average of 958,320 shares traded, while the 50-day average volume stands at 1,251,166.
BLUE stock has increased by 14.58% in the last month. The company shares reached their 1-month lowest point of $17.27 on 09/16/21. With the stock rallying to its 52-week high on 01/12/21, shares of the company touched a low of $17.14 and a high of $59.32 in 52 weeks. In spite of this, the price is down -66.08% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
132 days have passed since bluebird bio Inc. (BLUE) last reported insider trading activity. Obenshain Andrew, who is President of SGD, most recently acquired $511 shares at $30.75 per share on Jun 04. In this transaction, the insider spent $15,715. Chief Scientific Officer, Gregory Philip D, disposed of 39 shares at a price of $30.15 on May 03. The insider now owns more than $1,176 worth of shares. Prior to that, President of SGD Obenshain Andrew went on to Sale 29 shares at $30.15 each on May 03. An amount of $874 was transacted.
bluebird bio Inc. (BLUE) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 1.50. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 26.77, the price-to-book (PB) ratio at 1.38.
The quick ratio of bluebird bio Inc. for the three months ended June 29 was 3.60, and the current ratio was 3.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 59.40% against a 5-year average of 97.1%. bluebird bio Inc.’s EBITDA margin for the year ending June 29 is -243.35%. Its gross profit as reported stood at $245.34 million compared to revenue of $250.73 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, bluebird bio Inc.’s return on assets was -49.40%, compared to -29.8% over the last five years. In the past year, the return on investment has been -46.00%, and the 5-year average is -34.0%. Meanwhile, the return on equity (ROE) for the past 12 months has been -66.50% and the 5-year average holds at -37.2%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, bluebird bio Inc. had $486.23 million in cash. The analyst consensus anticipated bluebird bio Inc.’s latest quarter earnings to come in at -$3.25 per share, but it turned out to be -$3.58, a -10.20% surprise. For the quarter, EBITDA amounted to -$234.84 million. Shareholders own equity worth $67.58 million.
From a technical analysis perspective, let’s take a brief look at bluebird bio Inc. (BLUE) price momentum. RSI 9-day as of the close on 13 October was 65.88%, suggesting the stock is Neutral, with historical volatility in this time frame at 35.08%.
As of today, BLUE’s price is $19.69 +8.87% or $1.64 from its 5-day moving average. BLUE is currently trading +13.03% higher than its 20-day SMA and -36.23% lower than its 100-day SMA. However, the stock’s current price level is -19.87% below the SMA50 and -56.02% below the SMA200.
The stochastic %K and %D were 86.66% and 82.08%, respectively, and the average true range (ATR) was 0.81. With the 14-day stochastic at 68.91% and the average true range at 0.82, the RSI (14) stands at 59.51%. The stock has reached 0.96 on the 9-day MACD Oscillator while the 14-day reading was at 0.99.
The consensus rating for bluebird bio Inc. (BLUE) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BLUE, while 17 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is BLUE’s price target for the next 12 months?
Analysts predict a range of price targets between $18.00 and $37.00, with a median target of $22.00. Taking a look at these predictions, the average price target given by analysts for bluebird bio Inc. (BLUE) stock is $22.80.